Media
Amylyx Donates CENTAUR Records to PRO-ACT Trials Database for ALS | Data From ALS Trial's Placebo Arm Now Freely Available to Researchers | ALS News Today
Amylyx's ALS drug faces tough FDA scrutiny—again
ALS drug wins FDA approval despite questionable data
Amylyx Company Profile: Stock Performance & Earnings | PitchBook
Amylyx Enrolls First ALS Patients in Phase 2 Extension Trial of AMX0035
Media
Amylyx Pharmaceuticals | LinkedIn
Amylyx wins approval for first ALS drug - Boston Business Journal
Amylyx – AMX0035 August 2022
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035
Amylyx eyes IPO to support ALS drug filings across the world after FDA U-turn | Fierce Biotech
Amylyx Stock: ALS Drug Application Hangs In The Balance (NASDAQ:AMLX) | Seeking Alpha
Amylyx (@AmylyxPharma) / Twitter
Amylyx Updates - I AM ALS
ALS drug wins FDA approval despite questionable data | FOX8 WGHP
Amylyx Seeks U.S. Approval of AMX0035 for ALS With FDA Filing
Amylyx - FINN Partners
Media
European Medicines Agency Grants Orphan Drug Designation to Amylyx Pharmaceuticals' AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) | Business Wire
Amylyx to Seek AMX0035's Approval for ALS in Europe
/cloudfront-us-east-2.images.arcpublishing.com/reuters/IOKLMV5D5RNP7FTEWUHMHQCFGU.jpg "Amylyx's ALS drug gets U.S. FDA panel's backing in rare turnaround | Reuters")
Amylyx's ALS drug gets U.S. FDA panel's backing in rare turnaround | Reuters
Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS | Business Wire
Amylyx - FINN Partners
Amylyx Pharmaceuticals Announces First Patients Enroll in Open Label Extension of CENTAUR Phase 2 Clinical Trial of AMX0035 for Treatment of Amyotrophic Lateral Sclerosis | Business Wire
